Christos K, Chemo Open Access 2015, 5:1 DOI: 10.4172/2167-7700.1000177

Short Communication Open Access

## Follow up of Testicular Tumours for How Long it is Necessary?

## Kalaitzis Christos

Department of Urology, University of Thrace, 68100 Alexandroupolis, Greece

\*Corresponding author: Kalaitzis Christos, Department of Urology, University of Thrace, 68100 Alexandroupolis, Greece, Tel: +30 6973314539; E-mail: chkalaitzis@hotmail.com

Received date: 06 August, 2015; Accepted date: 16 December, 2015; Published date: 21 December, 2015

Copyright: © 2015 Kalaitzis Christos. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

## Introduction

Most testis tumors are diagnosed in early stages. Following orchiectomy excellent cure rates are achieved. In metastatic disease a multidisciplinary therapeutic approach is required and offers acceptable survival rates. The European Urological Association (EUA) recommends a follow-up up to 10 years for patient with nonmetastatic testicular tumors (state I). For patients with metastatic seminomatous and non-seminomatous disease the recommendation is an intensive follow-up for the first 5 years after surgical therapy and chemotherapy and thereafter physical examination, measurement of tumor markers and chest X-ray and, if indicated, CT abdomen, pelvis and chest once pro year without, however, specifying for how long [1], perhaps lifelong. In patient reported in the article [2] follow-up was limited to 5 years and that was clearly too short. A metastatic disease is a systemic disease. Late relapses are possible. The probability is between 1.3% and 7% [3-5]. Late relapses of non-seminomatous tumours are more frequent [3]. However, single case reports and small series did not allow for reliable conclusions regarding duration of follow-up, incidence and management of late relapses. Late relapses

after cisplatin-based chemotherapy are mostly chemo refractory and the overall prognosis is poor. For that reason resectable tumors should be removed surgically.

## References

- Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, et al. (2011) Guidelines on testicular cancer 2011. European Association of Urology 60: 304-319.
- Kalaitzis C, Bantis A, Tsakaldimis G, Giannakopoulos S, Sivridis E, et al. (2009) Osteolytic bone destruction resulting from relapse of a testicular tumour 23 years after inguinal orchiectomy and adjuvant chemotherapy: a case report. J Med Case Rep 3: 8702.
- Lipphard ME, Albers P (2004) Late relapse of testicular cancer. World J Urol 22: 47-54.
- Clemm GA, Schmeller N, Hentrich M, Lamerz R, Willmanns W (1997) Late relapse of germ cell tumours after cisplatin-based chemotherapy. Ann Oncol 8: 41-47.
- Oldenburg J, Alfsen GC, Waehre H, Fossa SD (2006) Late recurrences of germ cell malignancies: a population-based experience of over three decades. Br J Cancer 94: 820-827.